Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Debt | Alive

Total Raised


Last Raised

$3.45M | 2 yrs ago

About OncoSynergy

OncoSynergy is an oncology therapeutics spinout from UCSF. The company was founded in 2011 to provide solutions for treatment-resistant cancer through the development of oncology therapeutics, called Resistance Mechanism Inhibitors (RMIs). RMIs are unique multi-action, tumor-agnostic drug platforms that have shown preclinical promise as monotherapy and in strategic combinations. The company was founded in 2011 and is based in Stamford, Connecticut.

OncoSynergy Headquarters Location

2 Ravenglass Drive

Stamford, Connecticut, 06903,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OncoSynergy

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoSynergy is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

OncoSynergy Patents

OncoSynergy has filed 4 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Monoclonal antibodies
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Experimental cancer drugs, Oncology, Clusters of differentiation, Monoclonal antibodies, Transcription factors


Application Date


Grant Date



Related Topics

Experimental cancer drugs, Oncology, Clusters of differentiation, Monoclonal antibodies, Transcription factors



Latest OncoSynergy News

New guideline for treatment of brain metastases emphasizes key role of local therapies

May 11, 2022

Source: Healio Interview Disclosures: Vogelbaum reports honoraria from Celgene, Cellinta, Plus Therapeutics and Tocagen; and research funding from Celgene, Denovo Biopharma, Olympus and OncoSynergy. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio ASCO, in collaboration with the Society for Neuro-Oncology and American Society for Radiation Oncology, has issued a guideline that emphasizes the significance of local therapies for patients with symptomatic brain metastases. The societies convened a panel of experts from neurosurgery, neurology, neuro-oncology, medical oncology and radiation oncology to develop the guidance, based on results of 32 randomized clinical trials published in 2008 or later that included data on treatment for brain metastases from nonhematologic solid tumors. “During the past few decades, effective treatment of brain metastases has been limited to the use of surgery and various forms of radiotherapy, and prior guidelines were generated largely by experts in neurosurgery and radiation oncology,” Michael A. Vogelbaum, MD, PhD, chief of neurosurgery and program leader of the department of neuro-oncology at Moffitt Cancer Center, told Healio. “Recent advances in the development of targeted therapies and immunotherapies for cancers that have a propensity to spread to the brain led to the discovery that treatment with some of these agents can produce intracranial responses in some patients.” Vogelbaum spoke with Healio about what prompted the creation of the guideline, published in Journal of Clinical Oncology, the key recommendations, and continuing challenges for this patient population. Healio: What prompted this guideline? Vogelbaum: Although the data indicating treatment with certain systemically administered agents can produce intracranial responses in some patients have been exciting, they also created the risk of a change in the approach to initial treatment without a clear understanding of the role of other modalities that have been shown to be highly effective in producing durable intracranial disease control. A multidisciplinary group of experts recognized the need for a more comprehensive set of guidelines that included all modalities — medical, surgical and radiation-based — to help ensure the highest quality of care of patients with brain metastases. Healio: What are the key recommendations? Vogelbaum: The single most important recommendation relates to the use of first-line medical therapy in patients who would otherwise be eligible for a localized therapy, such as surgery or radiosurgery. For asymptomatic patients who have brain metastasis from a cancer that is likely to be responsive to a systemically administered targeted therapy or immunotherapy, it may be appropriate to use medical therapy alone, although consultation with a multidisciplinary team that includes neuro-oncology, neurosurgery and/or radiation oncology is recommended. Patients with symptomatic brain metastases who are eligible for treatment with surgery and/or radiosurgery should be managed with those established treatments — potentially in combination with a systemically administered therapy — but the evidence does not currently support use of systemically administered therapy alone in this group of patients. Healio: What topics do key secondary recommendations address? Vogelbaum: Other recommendations focus on specific situations in which use of targeted therapies or immunotherapies is supported by emerging clinical trial data. Additionally, some surgery- and radiation therapy-specific recommendations largely build upon those made in previous specialty-specific guideline processes. Healio: What are the continuing challenges for this patient population? Vogelbaum: Multiple questions still need to be answered to optimize the treatment of patients with brain metastases. The most obvious relate to the best ways to sequence and/or combine modalities. We also need to obtain higher-quality data with randomized trials that establish the relative efficacy and durability of treatment with use of systemic therapies vs. localized therapies, such as radiosurgery. Finally, we need to more fully understand the neurocognitive impact of each treatment modality individually or in combination. Reference: For more information: Michael A. Vogelbaum, MD, PhD, can be reached at Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612; email: Read more about

OncoSynergy Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

OncoSynergy Rank

  • When was OncoSynergy founded?

    OncoSynergy was founded in 2011.

  • Where is OncoSynergy's headquarters?

    OncoSynergy's headquarters is located at 2 Ravenglass Drive, Stamford.

  • What is OncoSynergy's latest funding round?

    OncoSynergy's latest funding round is Debt.

  • How much did OncoSynergy raise?

    OncoSynergy raised a total of $26.71M.

  • Who are the investors of OncoSynergy?

    Investors of OncoSynergy include NLabs, Connecticut Innovations,, JLabs and University of California, San Francisco.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.